Every material Form 8-K Ginkgo Bioworks Holdings, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ginkgo Bioworks reported third quarter 2026 revenue of $28 million, down 6% from $29 million a year earlier but up from $20 million in the second quarter. Its GAAP net loss from continuing operations narrowed to $41 million from $73 million, and Adjusted EBITDA improved to a loss of $22 million from a loss of $53 million, while the company also reaffirmed its 2026 cash burn guidance of $150 million to $125 million.
Q3 2026 revenue of $28 million vs. $29 million in Q3 2025, a 6% decrease
GAAP net loss from continuing operations of $41 million vs. $73 million a year earlier; net loss per share of $0.64 vs. $1.45
Adjusted EBITDA loss of $22 million vs. $53 million in the prior-year quarter; cash burn of $27 million in Q3
Cash and marketable securities of $285 million as of September 30, 2026; full-year 2026 cash burn guidance of ($150)-($125) million reaffirmed
Ginkgo Bioworks announced it will hold a presentation and Q&A session on November 5, 2026, to review business performance for the third quarter ended September 30, 2026. The filing announces the timing only and does not disclose any quarterly financial results.
Presentation and Q&A session set for Thursday, November 5, 2026, beginning at 4:30 p.m. ET
Webcast details and a replay will be posted on Ginkgo's investor relations website
Shareholders can submit questions via X (hashtag #GinkgoResults) or by email to investors@ginkgobioworks.com
Ginkgo Bioworks reported second quarter 2026 results on August 5, 2026. Revenue fell 48% to $20 million from $39 million, which the company attributed mainly to program rationalization tied to its restructuring, while its net loss from continuing operations and its Adjusted EBITDA loss both widened. Shareholders face a shrinking revenue base and larger losses, although the company reaffirmed its 2026 cash burn guidance.
Second quarter revenue of $20 million, compared with $39 million a year earlier, a decrease of 48%
Net loss from continuing operations of $57 million, compared with $53 million a year earlier
Adjusted EBITDA loss of $36 million, compared with $25 million a year earlier
Cash, cash equivalents and marketable securities of $302 million at June 30, 2026; full-year 2026 cash burn guidance of $125 million to $150 million reaffirmed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ginkgo Bioworks Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →